Prospective Stage-Stratified Histopathologic Study and Proposed Disease-Evolution Model of Gluteal Permanent Synthetic Filler Complications

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorResearch Inc

About this trial

This prospective biospecimen cohort will collect and analyze tissue from adults undergoing clinically indicated surgery for gluteal permanent synthetic filler disease. Two blinded pathologists will score foreign material burden, inflammation, fibrosis, necrosis, vascular and lymphatic injury, and deep-tissue involvement. Histopathologic severity will be compared across clinical-radiologic stages and time since injection. The study will propose a cross-sectional disease-evolution framework and assess the reproducibility of the scoring system.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Prior gluteal injection of a permanent or unknown nonresorbable filler.

Clinically indicated biopsy or surgical excision yielding tissue suitable for histopathologic evaluation.

Available history of approximate injection date and standardized preoperative clinical staging.

Written consent for tissue analysis and optional future use of deidentified specimens.

Disqualifiers

Specimen composed only of scar or skin without tissue from the filler-affected region.

Insufficient tissue quality for routine histology.

Acute bacterial infection that precludes distinction of the underlying chronic tissue response unless infection is itself a prespecified advanced-stage feature.

Prior oncologic radiation to the sampled gluteal region.

Trial population

Adults undergoing biopsy or surgical removal of gluteal tissue affected by permanent synthetic filler, spanning early exposure through advanced disease with ulceration or necrosis.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Standardized Tissue Sampling During Clinically Indicated Surgery

    Procedure/Surgery

    Samples will be obtained from predefined superficial, interface, deep, and visibly abnormal regions without extending the clinically indicated excision. Each sample will be oriented and linked to an MRI/operative map. Linked arm/group(s): Prospective Histopathology Cohort.

  • Blinded Histopathologic Scoring

    Other intervention

    Two pathologists will independently grade foreign material burden, granulomatous inflammation, fibrosis, fat necrosis, vascular injury, lymphatic involvement, muscle injury, and skin necrosis on 0-to-3 ordinal scales. The proposed composite ranges from 0 to 24; the manual will be locked before the first analytic read. Linked arm/group(s): Prospective Histopathology Cohort.

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: Prospective Histopathology Cohort2 interventions

Trial outcomes

Primary outcomes

1

Composite Histopathologic Severity Score by Clinical-Radiologic Stage

Sum of eight prespecified 0-to-3 domain scores: foreign material burden, granulomatous inflammation, fibrosis, fat necrosis, vascular injury, lymphatic involvement, muscle injury, and skin necrosis. Total score ranges from 0 to 24; higher scores indicate more severe tissue injury.

Time frame
At the index operation and final blinded histopathology assessment of the surgical specimen. 3 months

Secondary outcomes

1

Prevalence of Individual Histopathologic Features

Proportion of participants with each prespecified feature and distribution of each 0-to-3 domain grade.

Time frame
At final histopathology assessment of the index surgical specimen. 3 months

Other outcomes

1

Histopathologic Phenotype Classification

Data-driven clusters or latent classes based on the eight domains, integrated with clinical and MRI stage to generate a proposed disease-evolution framework.

Time frame
After completion of tissue collection and database lock, using data from the index specimen. 1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: